TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404086

Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil Placebo
Description: The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.

Intervention type: DRUG
Group type: OTHER
Intervention: Solriamfetol
Description: The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.

Intervention type: DRUG
Group type: OTHER
Intervention: Solriamfetol Placebo
Description: The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.

Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.

Intervention type: DRUG
Group type: OTHER
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tailored lighting (TL) Active
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study: NCT04717908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 400 mg once daily for 2 weeks then 200mg 3 times per week;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 1500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg daily
Study: NCT05653934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative use of virtual reality headset
Description: Patient use the virtual reality headset the day before and / or the day of the surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgery
Description: Patient are operated as needed for treatment of colorectal cancer (usual care)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: Patient are operated as needed for treatment of colorectal cancer (usual care)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-operative use of virtual reality headset
Description: Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
Study: NCT04888767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training Hight Intensity Program
Description: * Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible
Study: NCT04869995

Intervention type: OTHER
Intervention: Interview
Description: An individual semi-structured interview per surgeon, according to an interview guide.
Study: NCT05754528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care administration of Endocrine therapy
Description: Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-frequency escalation administration of Endocrine therapy
Description: Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
Study: NCT05066061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: usual process

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiolytic and analgesic gas
Description: add relaxing gas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality mask
Description: use Virtual reality mask Oculus Quest with age-appropriate software
Study: NCT05646485

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis
Description: Urine analysis (every 6 months for 2 years); Patients with \<3 red blood cells (RBCs) per high-powered field (HPF) will repeat screening at 6-month intervals for an average of 2 years.~If RBCs are 3-25 RBSc/HPF- subjects will undergo- \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\].~If \>25 RBCs, subjects will get - \[cystoscopy + Upper tract imaging\].
Study: NCT04807595

Intervention type: OTHER
Intervention: None (Observational study)
Description: The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
Study: NCT05453487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coadministration
Description: the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: received three dose of rabies vaccine
Study: NCT06113549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee Joint Distraction (KD)
Description: Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
Study: NCT05954312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130037
Description: Oral tablets
Study: NCT06340529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
Study: NCT04717908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: ≤50kg 500 mg daily, \>50kg 750mg daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 100 mg daily;
Study: NCT06340529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
Study: NCT04581590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
Study: NCT04469842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
Study: NCT06113549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee Prosthesis
Description: A total or unicompartmental knee prosthesis
Study: NCT06389227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic ecological approach (DEA)
Description: The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional training group
Description: The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
Study: NCT03814850

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard Manual Aneroid Sphygmomanometer
Description: Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Manual Aneroid Sphygmomanometer
Description: Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
Study: NCT05472415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognicise
Description: a combination of cognition and exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognicise
Description: a combination of cognition and exercise training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arch support insoles
Description: The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
Study: NCT04469842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
Study: NCT05522972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Vision Training
Description: A new approach for improving amblyopic vision using video games

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Learning
Description: A new approach for improving amblyopic vision with perceptual learning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion Therapy
Description: Conventional treatment for amblyopia
Study: NCT05879432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT Peptide
Description: LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution
Study: NCT04469842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Hydrochloride
Description: Standard immunosuppression of the anti-proliferative class.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil Hydrochloride
Description: Standard immunosuppression of the anti-proliferative class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard immunosuppression (corticosteroid class).
Study: NCT06559930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Neurological Rehabilitation + Dual Task Focused Training
Description: Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Neurological Rehabilitation
Description: Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
Study: NCT05979311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine will be administered once daily.
Study: NCT04768985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Acalabrutinib tablet
Description: Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Acalabrutinib tablet
Description: Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Acalabrutinib capsule
Description: Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Acalabrutinib capsule
Description: Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
Study: NCT05979311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir
Description: Bictegravir will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide will be administered once daily.
Study: NCT06562010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCT-SAD-PK
Description: The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
Study: NCT04469842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard immunosuppression (corticosteroid class).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Standard immunosuppression of the anti-proliferative class.
Study: NCT05819684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602 for injection
Description: be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602 for injection
Description: be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602 for injection
Description: be administered via intravenous (IV) infusion
Study: NCT05776797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)
Description: Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)
Description: Optimal medication therapy according to the prescription of the physician.
Study: NCT05868720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, Aripiprazole
Description: The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, Aripiprazole
Description: The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
Study: NCT04469842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Standard immunosuppression of the anti-proliferative class.
Study: NCT05683418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOS-358
Description: Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
Study: NCT06553547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo solution
Study: NCT05635162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
Study: NCT05501704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Taken orally
Study: NCT05565677

Intervention type: DEVICE
Intervention: micro-computed tomography scanning of lung tissue specimens
Description: Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
Study: NCT05804786

Intervention type: DEVICE
Intervention: Guided bronchoscopy
Description: It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
Study: NCT04518072

Intervention type: OTHER
Intervention: Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
Description: assessed biomarker in clinical samples

Intervention type: OTHER
Intervention: Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
Description: assessed biomarker in clinical samples
Study: NCT04431518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JULUCA 50Mg-25Mg Tablet
Description: One dose of JULUCA will be taken daily for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JULUCA 50Mg-25Mg Tablet
Description: One dose of JULUCA will be taken daily for up to 14 days
Study: NCT05809180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 ivgtt d1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-miniCHOP-like regimen
Description: rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-miniCHOP-like regimen
Description: rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Study: NCT05621252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: 160 mg PLN-74809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo